Left Atrial Appendage Occlusion (LAAO)
Details
Percutaneous or surgical occlusion of the left atrial appendage (LAA) to prevent cardioembolic stroke in atrial fibrillation. The LAA is the source of ~90% of AF-related cardiac thrombi; physical exclusion of the LAA from systemic circulation eliminates the thromboembolic nidus without requiring lifelong systemic anticoagulation. Traditionally advocated for patients with contraindications to oral anticoagulation; the 2026 CHAMPION-AF trial established noninferiority in NOAC-eligible patients and shifted the indication landscape substantially.
Key Facts
Mechanism and Rationale
- ~90% of AF-related cardiac thrombi form in the LAA; exclusion theoretically eliminates the thromboembolic source without the haemorrhagic risk of systemic anticoagulation.
- After successful device implantation, short-term antithrombotic therapy (NOAC or DAPT) is used to allow endothelialization of the device, then discontinued — leaving the patient free of long-term anticoagulation.
- Stroke reduction is a "delayed benefit": early periprocedural and post-implant antithrombotic-related bleeding risk must be outweighed by long-term stroke and bleeding prevention gains. (sources/laao-closureaf-nejm-2026, rating: very high)
Devices
- Watchman / Watchman FLX (Boston Scientific): endovascular plug; most studied device; only device used in CHAMPION-AF; approved for AF stroke prevention with or without contraindication to OAC.
- Amulet (Abbott/St. Jude Medical): lobe-and-disc design; shown non-inferior to Watchman in the Amulet IDE trial; used in CLOSURE-AF.
- Amplatzer Cardiac Plug / LAmbre (LifeTech): alternative devices used at selected CLOSURE-AF sites.
- Surgical LAA closure: ligation or stapling at cardiac surgery; Atriclip device; driven by LAAOS III data. (sources/AF-ESC-2024, sources/AF-AHA-2023, rating: very high)
Guideline Recommendations (as of 2026)
- Percutaneous LAAO — AHA 2023: Class IIa/B-NR for AF patients with contraindication to long-term OAC — upgraded from IIb; anticipated downgrade following CLOSURE-AF 2026. (sources/AF-AHA-2023, rating: very high)
- Percutaneous LAAO — ESC 2024: Class IIb/C for patients with contraindications to all OAC options; pending update based on CLOSURE-AF and CHAMPION-AF 2026 results. (sources/AF-ESC-2024, rating: very high)
- Surgical LAA closure during cardiac surgery — ESC 2024: Class I/B as adjunct to OAC — driven by LAAOS III (HR 0.67 for ischaemic stroke/SE over 3.8 years). (sources/AF-ESC-2024, rating: very high)
- Surgical LAA closure during cardiac surgery — AHA 2023: Class I/A as adjunct to OAC. (sources/AF-AHA-2023, rating: very high)
- Surgical LAAO during valve surgery — ESC VHD 2025: Class I/B — extended LAAOS III data to patients with AF undergoing any valve surgery to prevent cardioembolic stroke and systemic thromboembolism. (sources/vhd-esc-2025, rating: very high)
Procedural Outcomes (Watchman FLX — CHAMPION-AF)
- Implantation attempt success: 98.8% (1,386/1,403 attempts).
- Effective closure (residual leak ≤3 mm) at 4 months: 98.6% (998/1,012 patients imaged).
- Pericardial effusion requiring intervention within 30 days: 0.7% (10/1,499 device group).
- Device-related thrombus at 4 months: 4.8% on CT/TEE (likely overestimated due to COVID-19 era increased CT use detecting benign endothelialization); clinically relevant thrombus (resumed OAC): 1.8%; device thrombus leading to stroke: 2 patients.
- Note: CT detects subtle hypoattenuated thickening (benign endothelialization) that TEE does not — imaging modality is a key determinant of thrombus rate. (sources/laao-championaf-nejm-2026, rating: very high)
Post-Implant Antithrombotic Strategy
- NOAC-based (preferred post-CHAMPION-AF): NOAC × ~3 months post-implant, then antiplatelet monotherapy or cessation. Used in 85% of CHAMPION-AF device group at discharge. Associated with low early bleeding and superior long-term bleeding profile vs DAPT.
- DAPT-based (older approach): DAPT × 3–6 months post-implant, then single antiplatelet. Used in 79.6% of CLOSURE-AF device group. Associated with higher early bleeding and inferior net outcomes in high-risk elderly patients. (sources/laao-closureaf-nejm-2026, sources/laao-championaf-nejm-2026, rating: very high)
Landmark RCT Evidence
| Trial | Population | Comparator | NI result | Key finding |
|---|---|---|---|---|
| PROTECT AF | Moderate-risk AF; warfarin-eligible | Warfarin | NI demonstrated | First Watchman RCT; DOAC not available |
| PREVAIL | Similar to PROTECT AF | Warfarin | NI demonstrated | Confirmed PROTECT AF; DOAC comparator absent |
| PRAGUE-17 (2022) | Moderate-risk AF (CHA₂DS₂-VASc ~4.7) | NOACs | NI at 4 years | First vs NOAC; smaller n |
| OPTION (2025) | AF ablation patients; CHA₂DS₂-VASc 3.5; HAS-BLED 1.2; n=1,600; 106 sites; 10 countries | OAC (95% NOAC) | NI demonstrated (P<0.001) | LAAO superior for non-procedure-related bleeding (HR 0.44); ischemic stroke 1.2% vs 1.3% — very low in both arms |
| CLOSURE-AF (2026) | Highest-risk: CHA₂DS₂-VASc 5.2; HAS-BLED 3.0; OAC unsuitable; n=888 | DOACs (85.1%) | NI failed (P=0.44) | LAAO numerically worse; periprocedural + DAPT bleeding negated stroke benefit |
| CHAMPION-AF (2026) | NOAC-eligible: CHA₂DS₂-VASc 3.5; HAS-BLED 1.3; n=3,000 | NOACs | NI demonstrated (P<0.001) | LAAO superior for bleeding (HR 0.55); ischaemic stroke numerically higher (3.2% vs 2.2%) |
(sources/laao-closureaf-nejm-2026, sources/laao-championaf-nejm-2026, rating: very high)
OPTION Key Results (2025 — NEJM)
- Trial-specific context: LAAO performed concomitantly with (40.9%) or sequentially after (59.1%) AF catheter ablation; post-implant antithrombotic: OAC + aspirin 90 days → aspirin alone until 12 months.
- Primary safety (non-procedure-related major + CRNM bleeding at 36 months): 8.5% vs 18.1%; HR 0.44 (95% CI 0.33–0.59); P<0.001 superiority. 56% relative risk reduction.
- Primary efficacy (death/stroke/SE at 36 months): 5.3% vs 5.8%; HR 0.91 (95% CI 0.59–1.39); P<0.001 noninferiority.
- Ischemic stroke: 1.2% vs 1.3% — very low in both arms; no meaningful ischemic stroke excess with LAAO.
- Hemorrhagic stroke: 0.4% vs 0.4%.
- Secondary endpoint (ISTH major bleeding incl. procedure-related): 3.9% vs 5.0%; NI met (P<0.001); superiority not met (P=0.28).
- Device success 98.8%; complete seal 81% at 3m / 79.7% at 12m; device-related thrombus 1.9% at 12m.
- 84.8% of OAC group maintained anticoagulation throughout; 10.1% of device group still on OAC at 36m. (sources/laao-option-nejm-2025, rating: very high)
CHAMPION-AF Key Results (2026 — NEJM)
- Primary efficacy (CV death/stroke/SE at 3 years): 5.7% (device) vs 4.8% (NOAC); difference 0.9 pp; P<0.001 for NI. NI demonstrated. HR 1.20 (95% CI 0.87–1.66) — point estimate favours NOAC.
- Primary safety (non-procedure-related bleeding at 3 years): 10.9% vs 19.0%; HR 0.55 (95% CI 0.45–0.67); P<0.001 for superiority. Superiority demonstrated.
- Ischaemic stroke/SE: 3.2% vs 2.2% — numerically higher with LAAO (~0.3%/yr absolute excess).
- Haemorrhagic stroke: 0.4% vs 0.4% — equal.
- Net clinical benefit (efficacy + bleeding): 15.1% vs 21.8%; HR 0.66 (P<0.001 for NI) — device favoured overall. (sources/laao-championaf-nejm-2026, rating: very high)
CLOSURE-AF Key Results (2026 — NEJM)
- Primary composite (stroke/SE/major bleeding/CV death): 16.8 vs 13.3/100 pt-yr; RMST difference −0.36 years (95% CI −0.70 to −0.01); P=0.44 for NI — NI not demonstrated.
- Stroke: equal (2.6 vs 2.7/100 pt-yr).
- Major bleeding (BARC ≥3): 7.4 vs 6.2/100 pt-yr — LAAO numerically higher.
- CV/unexplained death: 9.5 vs 7.7/100 pt-yr — LAAO numerically higher.
- Post-implant antithrombotic: 79.6% DAPT (dominant early bleeding driver). (sources/laao-closureaf-nejm-2026, rating: very high)
Contradictions / Open Questions
- OPTION post-implant antithrombotic vs CHAMPION-AF: OPTION used OAC + aspirin 90 days → aspirin alone (bridge strategy), while CHAMPION-AF used NOAC post-implant. Both achieved NI and bleeding superiority, but the post-implant protocol differences make direct bleeding comparisons across trials imprecise. OPTION's OAC bridge may partially explain its 8.5% non-procedure-related bleeding rate (vs 10.9% in CHAMPION-AF device group), but patient populations differ (post-ablation lower-risk vs general AF). (sources/laao-option-nejm-2025, sources/laao-championaf-nejm-2026, rating: very high)
- OPTION complete seal rate (79.7% at 12m) lower than PINNACLE FLX (90%): Attributed to CT use (16% of OPTION patients at 12m vs TEE-dominant PINNACLE FLX) — CT detects smaller peridevice leaks. Clinical significance uncertain: ischemic stroke rates were equally low in both OPTION groups (1.2% LAAO vs 1.3% OAC). (sources/laao-option-nejm-2025, rating: very high)
- CHAMPION-AF (positive) vs CLOSURE-AF (negative) — same procedure, opposite NI conclusions (NEJM 2026): The divergence is mechanistically coherent but has major guideline implications. CHAMPION-AF (lower-risk, NOAC-eligible, NOAC post-implant) demonstrated NI and bleeding superiority; CLOSURE-AF (highest-risk, OAC-unsuitable, DAPT post-implant) failed NI with device numerically worse. Critical determinants: (1) patient risk profile — higher absolute baseline event rate in CLOSURE-AF amplified periprocedural harm relative to benefit; (2) post-implant antithrombotic strategy — NOAC post-implant (CHAMPION-AF) eliminated DAPT-driven early bleeding that negated LAAO benefit in CLOSURE-AF; (3) NI margin design — absolute (CHAMPION-AF) vs relative HR (CLOSURE-AF). The clinical implication is that LAAO may benefit NOAC-eligible moderate-risk patients, but is non-inferior at best — and potentially harmful — in the highest-risk anticoagulation-unsuitable elderly population for whom it was traditionally most recommended. (sources/laao-championaf-nejm-2026, sources/laao-closureaf-nejm-2026, rating: very high)
- Ischaemic stroke signal in CHAMPION-AF: LAAO showed a numerically higher ischaemic stroke rate (3.2% vs 2.2%; ~0.3%/yr absolute excess) vs NOAC over 3 years. The 5-year primary efficacy endpoint (ischaemic stroke/SE) is pending; this excess may widen over time, potentially affecting the net clinical benefit assessment.
- CHAMPION-AF NI margin permissiveness: The absolute NI margin (4.8 percentage points at 3-year event rate) translates to a permissive relative risk threshold (up to HR 1.4). Given lower-than-expected event rates (5.7% vs anticipated 12%), this NI design may allow a clinically meaningful stroke excess to still pass the NI test.
- Optimal post-implant antithrombotic regimen: NOAC-based post-implant therapy appears superior to DAPT in maintaining bleeding advantage, but the optimal duration and regimen remain undefined; DAPT appears clearly inferior in high-risk elderly patients.
- LAAO guideline reclassification pending: AHA 2023 Class IIa recommendation for OAC-contraindicated patients is directly challenged by CLOSURE-AF and is expected to be downgraded. The role of LAAO in NOAC-eligible patients (historically off-label) is now supported by CHAMPION-AF but requires guideline formalisation. (sources/laao-closureaf-nejm-2026, sources/laao-championaf-nejm-2026, rating: very high)
- Device-related thrombus imaging artefact: The 4.8% device-related thrombus rate in CHAMPION-AF (CT/TEE combined) is likely inflated by COVID-19 pandemic-driven increased CT use, which detects benign hypoattenuated endothelialization. True clinically relevant thrombus rate (resumed OAC) was 1.8%.
Connections
- Related to entities/Atrial-Fibrillation — primary indication; LAAO as stroke prevention alternative to anticoagulation
- Related to concepts/Anticoagulation-in-AF — LAAO as comparator and potential replacement for long-term OAC
- Related to concepts/AF-CARE — Avoid stroke pillar; LAAO as non-pharmacological option
- Related to concepts/Catheter-Ablation-AF — OPTION trial: LAAO as post-ablation OAC alternative
- Related to concepts/Left-Atrial-Appendage-Closure — mechanistic concept page
Sources
- sources/laao-option-nejm-2025 — OPTION: LAAO vs OAC (95% NOAC) in post-ablation AF; NI + non-procedure-related bleeding superiority (HR 0.44); Watchman FLX; rating very high
- sources/laao-championaf-nejm-2026 — CHAMPION-AF: LAAO vs NOAC in NOAC-eligible AF; NI + bleeding superiority; Watchman FLX; rating very high
- sources/laao-closureaf-nejm-2026 — CLOSURE-AF: LAAO vs DOAC in highest-risk AF; NI failed; rating very high
- sources/AF-ESC-2024 — ESC 2024 AF guidelines; pLAAO Class IIb/C; surgical LAA closure Class I/B
- sources/AF-AHA-2023 — AHA 2023 AF guidelines; pLAAO Class IIa/B-NR; surgical LAA closure Class I/A
- sources/vhd-esc-2025 — ESC VHD 2025; surgical LAAO during valve surgery Class I/B